33 documents

Read All
23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications...
Read More
17:43 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, mouse and cell culture studies suggest inhibiting JAG1 could help treat lung cancer. In samples from non-small cell lung cancer (NSCLC) patients, endothelial cell levels of the Notch 3 ligand...
Read More
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
Read More
20:33 , Apr 21, 2017 |  BC Week In Review  |  Clinical News

Tarextumab: Development discontinued

OncoMed said it will discontinue all clinical development of tarextumab after reporting data from 145 previously untreated patients with extensive-stage SCLC in the Phase II portion of the double-blind, placebo-controlled, U.S. Phase Ib/II PINNACLE trial...
Read More
19:00 , Apr 17, 2017 |  BC Extra  |  Clinical News

OncoMed reeling after latest Phase II failure

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) sank $0.83 (17%) to $4.01 on Monday after it said tarextumab (OMP-59R5) failed to significantly extend progression-free survival (PFS) in the Phase II PINNACLE trial as a first-line treatment for extensive-stage...
Read More
22:57 , Apr 7, 2017 |  BioCentury  |  Emerging Company Profile

Up a notch

By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG ’s molecules could treat more patients than therapies against individual Notch receptors or ligands, with less toxicity than other pan-Notch...
Read More
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Tarextumab: Completed Phase Ib/II enrollment

OncoMed completed enrollment of 145 patients with extensive-stage SCLC in the Phase II portion of the double-blind, placebo-controlled, U.S. Phase Ib/II PINNACLE trial of 15 mg/kg IV tarextumab. Patients will receive tarextumab every 3 weeks...
Read More
07:00 , Aug 18, 2016 |  BC Extra  |  Financial News

OncoMed raises $55M in follow-on

Cancer stem cell company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) raised $55 million through the sale of 5.5 million shares at $10 in a follow-on underwritten by Leerink, Wells Fargo and JMP Securities. The company proposed the...
Read More
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

Tarextumab: Updated Phase Ib/II data

Updated data from 27 patients with SCLC in the dose-escalation Phase Ib portion of the international Phase Ib/II PINNACLE trial showed that IV 5-15 mg/kg tarextumab every 3 weeks plus etoposide and cisplatin for up...
Read More
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Tarextumab: Phase Ib/II data

OncoMed said it will unblind the double-blind, U.S. Phase Ib/II ALPINE trial in 172 evaluable patients with previously untreated stage IV pancreatic cancer after a pre-planned interim analysis by a DSMB showed that there was...
Read More